(Reuters) – Eli Lilly and Co said on Thursday it had entered an agreement with the U.S. government to supply up to 600,000 doses of its developmental COVID-19 antibody drug, bebtelovimab, for at least $720 million.
(Reporting by Amruta Khandekar; Editing by Krishna Chandra Eluri)
